Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pharmacokinetics, safety and tolerability after single dose administration of afatinib in moderate and severe renal impairment in comparison to subjects with normal renal function (a mono-centric, open-label study in matched-group design)

Trial Profile

Pharmacokinetics, safety and tolerability after single dose administration of afatinib in moderate and severe renal impairment in comparison to subjects with normal renal function (a mono-centric, open-label study in matched-group design)

Completed
Phase of Trial: Phase I

Latest Information Update: 30 Jun 2017

At a glance

  • Drugs Afatinib (Primary)
  • Indications Renal impairment
  • Focus Pharmacokinetics
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 19 Jul 2016 Results published in the European Journal of Drug Metabolism and Pharmacokinetics
    • 11 Dec 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 09 Jul 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top